Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab, PD-1 Inhibitor, and Lenalidomide in TP53-aberrant R/R LBCL
NCT07240194Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Started Sep 2025; status: recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07240194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07240194.